P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY by J. Kuruvilla, P. Armand, A. F. Herrera, V. Ribrag, P. Brice, C. Thieblemont, B. Von Tresckow, E. Kim, P. Marinello, S. Chakraborty, R. Orlowski, P. L. Zinzani

Get full text

P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HOD... by F. J. Hernandez-Ilizaliturri, J. Kuruvilla, B. A. Christian, I. W. Flinn, S. E. Assouline, M. L. Ulrickson, D. J. Landsburg, M. Stuart, H. Lowman, N. Levin, D. Maetzel, N. N. Viller, A. MacLaren

Get full text

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY... by G. Gregory, J. Timmerman, D. Lavie, P. Borchmann, A. F. Herrera, L. Minuk, V. Vucinic, P. Armand, A. Avigdor, R. Gasiorowski, Y. Herishanu, C. Keane, J. Kuruvilla, J. Palcza, P. Pillai, P. Marinello, N. A. Johnson

Get full text

S216: CLINICAL ACTIVITY OF CC-99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (R/R NHL) – RESULTS FROM A PHASE... by J.-M. Michot, J. C. Chavez, C Carpio, S. Ferrari, T. A. Feldman, D. Morillo, J. Kuruvilla, A. Pinto, V. Ribrag, E Bachy, T. J. Buchholz, S. Carrancio, W.-C. Chou, C. Guarinos, F. Wu, S. Li, P. Patah, M. Pourdehnad, L. Nastoupil

Get full text

P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF... by M. Matasar, N. L. Bartlett, L. H. Sehn, S. J. Schuster, S. Assouline, P. Giri, J. Kuruvilla, M. Canales, S. Dietrich, K. Fay, M. Ku, L. J. Nastoupil, M. C. Wei, S. Yin, I. To, D. Turner, H. Huang, J. Min, E. Penuel, L. E. Budde

Get full text